Astri Therapeutics Inc (ATXS) Stock Price, Quote & News

Company Profile

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatm...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 349 1971

Fax: 617 273 2637

Website: www.astriatx.com

Address:

22 Boston Wharf Road, 10th floor, Boston, United States

ms1sd Oct. 9 at 6:58 PM

Anyone know of a scheduled event in the future that might provide positive data to the market on $ATXS?

0 · Reply

Magic8BallResponse Oct. 9 at 5:52 PM

$ATXS Great run..... long term triple

0 · Reply

BOXLinvestor Oct. 9 at 5:58 AM

$ATXS Astria Therapeutics (stock volume 10-08-25) 8.40 +12.4% | volume 820,142 | 90-day avg 326,017 × 2.5

0 · Reply

Magic8BallResponse Oct. 8 at 5:53 PM

$ATXS Looks like will test resistance .... $10

0 · Reply

Magic8BallResponse Sep. 23 at 1:16 PM

$TIL Back into $ATXS....

0 · Reply

Magic8BallResponse Sep. 20 at 6:24 PM

$ATXS Jill is sitting on a gold mine...... TO THE MOON

0 · Reply

Magic8BallResponse Sep. 19 at 7:02 PM

$ATXS THIS MIGHT BE THE TIME

0 · Reply

Magic8BallResponse Sep. 19 at 3:16 PM

$ATXS PT raisee to $20!!!!!

0 · Reply

JarvisFlow Sep. 17 at 3:46 PM

HC Wainwright & Co. has adjusted their stance on Astria Therapeutics ( $ATXS ), setting the rating to Buy with a target price of 16 → 20.

0 · Reply

Magic8BallResponse Sep. 17 at 3:23 PM

$TIL Testing support. Could reverse on news. $ATXS to the moon

0 · Reply

Astria Therapeutics to Present at Upcoming CSACI 80th Anniversary Scientific Meeting

Oct 8, 2025, 8:00 AM EDT - 3 days ago

Astria Therapeutics Initiates the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart in People with Hereditary Angioedema

Oct 3, 2025, 8:00 AM EDT - 8 days ago

Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA

Oct 2, 2025, 4:10 PM EDT - 8 days ago

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2025, 8:00 AM EDT - 9 days ago

Astria Therapeutics Now Enrolling HAE Patients in the European Union for the Phase 3 ALPHA-ORBIT Trial

Sep 17, 2025, 8:00 AM EDT - 24 days ago

Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology

Sep 5, 2025, 2:07 AM EDT - 5 weeks ago

Astria Therapeutics, Inc. (ATXS) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 8:00 AM EDT - 5 weeks ago

Astria Therapeutics to Present Initial Data from Phase 1a Trial of STAR-0310 at Upcoming European Academy of Dermatology & Venereology Congress 2025

Aug 27, 2025, 8:00 AM EDT - 6 weeks ago

Astria Therapeutics to Present at Upcoming Cantor Global Healthcare Conference

Aug 12, 2025, 4:10 PM EDT - 2 months ago

Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 6, 2025, 8:00 AM EDT - 2 months ago

Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan

Jul 7, 2025, 8:00 AM EDT - 3 months ago

Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit

Jun 18, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics to Participate in Upcoming Oppenheimer Innovators in Immunology & Inflammation Summit

Jun 13, 2025, 7:00 AM EDT - 4 months ago

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

Jun 6, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

May 28, 2025, 8:00 AM EDT - 4 months ago

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

May 23, 2025, 8:00 AM EDT - 5 months ago

Astria Therapeutics to Present at Upcoming C1 Inhibitor Deficiency and Angioedema Workshop

May 22, 2025, 8:00 AM EDT - 5 months ago

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

May 13, 2025, 4:10 PM EDT - 5 months ago

Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

May 1, 2025, 8:00 AM EDT - 5 months ago

Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology

Apr 30, 2025, 8:00 AM EDT - 5 months ago

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

Mar 11, 2025, 8:00 AM EDT - 7 months ago

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Feb 27, 2025, 8:00 AM EST - 8 months ago

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Feb 25, 2025, 8:00 AM EST - 8 months ago

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 8:00 AM EST - 8 months ago

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Feb 17, 2025, 10:32 PM EST - 8 months ago

Astria Therapeutics: A High-Conviction Bet On HAE

Feb 4, 2025, 8:00 AM EST - 8 months ago

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 3, 2025, 8:00 AM EST - 8 months ago

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Jan 23, 2025, 8:00 AM EST - 9 months ago

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Jan 13, 2025, 8:00 AM EST - 9 months ago

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Dec 11, 2024, 8:00 AM EST - 10 months ago

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Dec 10, 2024, 8:00 AM EST - 10 months ago

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Nov 27, 2024, 8:00 AM EST - 11 months ago

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Nov 13, 2024, 4:10 PM EST - 11 months ago

Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Nov 13, 2024, 8:00 AM EST - 11 months ago

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting

Oct 21, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Oct 16, 2024, 8:00 AM EDT - 1 year ago

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema

Sep 27, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming Global Angioedema Forum

Sep 19, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming Bradykinin Symposium

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 4:10 PM EDT - 1 year ago

Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Aug 12, 2024, 4:00 PM EDT - 1 year ago

Astria Therapeutics Chooses Ypsomed's YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema

Aug 7, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference

May 30, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

May 23, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

May 9, 2024, 4:10 PM EDT - 1 year ago

Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 8, 2024, 8:00 AM EDT - 1 year ago

Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting

ms1sd Oct. 9 at 6:58 PM

Anyone know of a scheduled event in the future that might provide positive data to the market on $ATXS?

0 · Reply

Magic8BallResponse Oct. 9 at 5:52 PM

$ATXS Great run..... long term triple

0 · Reply

BOXLinvestor Oct. 9 at 5:58 AM

$ATXS Astria Therapeutics (stock volume 10-08-25) 8.40 +12.4% | volume 820,142 | 90-day avg 326,017 × 2.5

0 · Reply

Magic8BallResponse Oct. 8 at 5:53 PM

$ATXS Looks like will test resistance .... $10

0 · Reply

Magic8BallResponse Sep. 23 at 1:16 PM

$TIL Back into $ATXS....

0 · Reply

Magic8BallResponse Sep. 20 at 6:24 PM

$ATXS Jill is sitting on a gold mine...... TO THE MOON

0 · Reply

Magic8BallResponse Sep. 19 at 7:02 PM

$ATXS THIS MIGHT BE THE TIME

0 · Reply

Magic8BallResponse Sep. 19 at 3:16 PM

$ATXS PT raisee to $20!!!!!

0 · Reply

JarvisFlow Sep. 17 at 3:46 PM

HC Wainwright & Co. has adjusted their stance on Astria Therapeutics ( $ATXS ), setting the rating to Buy with a target price of 16 → 20.

0 · Reply

Magic8BallResponse Sep. 17 at 3:23 PM

$TIL Testing support. Could reverse on news. $ATXS to the moon

0 · Reply

Magic8BallResponse Sep. 17 at 2:55 PM

$TIL Flirting with support... needs a buyer..... $ATXS looks like GOLD

0 · Reply

DARKP00L Sep. 17 at 1:43 PM

$ATXS 09:42 on Sep. 17 2025 ATXS stock has given up its prior loss. Astria Therapeutics shares were trading lower. The company announced initial results from the Phase 1a trial of STAR-0310 in healthy subjects. #tradeideas

0 · Reply

Magic8BallResponse Sep. 16 at 10:21 PM

$TIL $ATXS

0 · Reply

Magic8BallResponse Sep. 13 at 3:38 PM

$ATXS It's time for Jill to shine..... PT $9....

0 · Reply

Magic8BallResponse Sep. 13 at 3:36 PM

$TIL CFO sale + ATM = Shift to $SMMT & $ATXS

0 · Reply

Magic8BallResponse Sep. 13 at 1:28 PM

$TIL CFO selling not a great sign. ATM facility possible drag. $ATXS with a great looking chart.

0 · Reply

Magic8BallResponse Sep. 11 at 2:45 PM

$ATXS Chart looks goooood

0 · Reply

RunnerSignals Sep. 9 at 8:50 PM

$ATXS $DNTH $SION $SEZL $SDGR analysts see stars, but will these rockets launch? Strap in, it's gonna be a wild ride! https://stocksrunner.com/news/2025-09-09-unlocking-stocks-with-analyst-upgrades-and-short-term-upside-potential

0 · Reply

G101SPM Sep. 9 at 2:54 PM

G101SPM 8/6/2025, 8:36:54 AM $ATXS $7.17 bid. DAC $7.60. EXIT $14.00.

0 · Reply

NVDAMillionaire Sep. 5 at 3:16 PM

$ATXS Brilliant piece that captures ATXS's situation perfectly. So if you want to update your understanding of ATXS or get to know ATXS better, this is essential reading. https://beyondspx.com/quote/ATXS/astria-therapeutics-unlocking-value-through-a-differentiated-dual-asset-pipeline-nasdaq-atxs#analysis

0 · Reply

Magic8BallResponse Sep. 3 at 11:06 PM

$ATXS Let's get that $8

0 · Reply

Magic8BallResponse Aug. 24 at 1:51 PM

$ATXS This is a winner.

0 · Reply

Market Cap	367.39M
Revenue (ttm)	0.00
Net Income (ttm)	-94.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	235,500
Avg Vol	274,958
Day's Range	N/A - N/A
Shares Out	56.44M
Stochastic %K	10%
Beta	0.48
Analysts	Strong Sell
Price Target	$29.33